Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia

British Journal of Cancer

Volumn 114, Issue 6, 2016, Pages 605-611

  Ceccacci, Elena ^a,b   Minucci, Saverio ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

APL; cancer stem cells; epigenetics; HDACi; histone deacetylases; leukaemia

Indexed keywords

4 PHENYLBUTYRIC ACID; ABEXINOSTAT; ARSENIC TRIOXIDE; BELINOSTAT; ENTINOSTAT; GIVINOSTAT; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; PANOBINOSTAT; QUISINOSTAT; RESMINOSTAT; RICOLINOSTAT; ROMIDEPSIN; TACEDINALINE; VALPROIC ACID; VORINOSTAT;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STEM CELL; CANCER THERAPY; CELL SUBPOPULATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; GENETIC ASSOCIATION; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; NEOPLASM; NEXT GENERATION SEQUENCING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; ANIMAL; ENZYMOLOGY; GENETICS; METABOLISM;

ANIMALS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA;

EID: 84959140658     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.36     Document Type: Article

References (30)

1. Botrugno OA, Santoro F, Minucci S (2009) Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 280(2): 134-144.
2. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery 2(5): 401-404.
3. Chiaradonna F, Cirulli C, Palorini R, Votta G, Alberghina L (2015) New insights into the connection between histone deacetylases, cell metabolism, and cancer. Antioxid Redox signal 23(1): 30-50.
4. Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1): 12-27.
5. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C (2009) Histone deacetylase inhibitors and genomic instability. Cancer Lett 274(2): 169-176.
6. Falkenberg KJ, Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13(9): 673-691.
7. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37(4): 391-400.
8. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10(1): 32-42.
9. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY (1988) Use of all-Trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572.
10. Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, Pruneri G, Viale G, Appella E, Pelicci P, Minucci S (2004) Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J 23(5): 1144-1154.
11. Kebede AF, Schneider R, Daujat S (2015) Novel types and sites of histone modifications emerge as players in the transcriptional regulation contest. FEBS J 282(9): 1658-1674.
12. Kreso A, Dick JE (2014) Evolution of the cancer stem cell model. Cell Stem Cell 14(3): 275-291.
13. Leiva M, Moretti S, Soilihi H, Pallavicini I, Peres L, Mercurio C, Dal Zuffo R, Minucci S, de The H (2012) Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia 26(7): 1630-1637.
14. Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, Santoro F, Vidacs E, Stanley K, House CM, Rusche JR, Vakoc CR, Zuber J, Minucci S, Johnstone RW (2015) Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood 126(21): 2392-2403.
15. Mercurio C, Minucci S, Pelicci PG (2010) Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 62(1): 18-34.
16. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1): 38-51.
17. Müller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denkert C (2013) Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 13: 215.
18. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi PP, Rochette-Egly C, Zhu J, de Theá H (2008) Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 14(12): 1333-1342.
19. Rincon-Arano H, Halow J, Delrow JJ, Parkhurst SM, Groudine M (2012) UpSET recruits HDAC complexes and restricts chromatin accessibility and acetylation at promoter regions. Cell 161(6): 1214-1228.
20. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, Caballero R, Alaminos M, Setien F, Paz MF, Herranz M, Palacios J, Arango D, Orntoft TF, Aaltonen LA, Schwartz Jr. S, Esteller M (2006) A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38(5): 566-569.
21. Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M, Toi M (2005) Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24(28): 4531-4539.
22. Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S, Altucci L, Pelicci PG, Chiocca S, Johnstone RW, Minucci S (2013) A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121(17): 3459-3468.
23. Subramanian S, Bates S, Wright J, Espinoza-Delgado I, Piekarz R (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3: 2751-2767.
24. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner HJ, Ogden A, Schepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH (1997) All-Trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337(15): 1021-1028.
25. Valente S, Mai A (2014) Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer disease: a patent review (2011-2013). Expert Opin Therap Patents 24(4): 401-415.
26. Wagner GR, Payne RM (2013) Widespread and enzyme-independent Ne-Acetylation and Ne-succinylation of proteins in the chemical conditions of the mitochondrial matrix. J Biol Chem 288(40): 29036-29045.
27. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K (2009) Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138(5): 1019-1031.
28. West AC, Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124(1): 30-39.
29. Winter M, Moser MA, Meunier D, Fischer C, Machat G, Mattes K, Lichtenberger BM, Brunmeir R, Weissmann S, Murko C, Humer C, Meischel T, Brosch G, Matthias P, Sibilia M, Seiser C (2013) Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis. EMBO J 32(24): 3176-3191.
30. Yang XJ, Seto E (2008) The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and man. Nat Rev Mol Cell Biol 9(3): 206-218.